Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy
Background: Oestradiol with or without an anti-androgen (cyproterone acetate or spironolactone) is commonly prescribed in transfeminine individuals who have not had orchidectomy; however, there is no evidence to guide optimal treatment choice. Objective: We aimed to compare add-on cyproterone acet...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2019-07-01
|
| Series: | Endocrine Connections |
| Subjects: | |
| Online Access: | https://ec.bioscientifica.com/view/journals/ec/8/7/EC-19-0272.xml |
| _version_ | 1818247174805258240 |
|---|---|
| author | Lachlan Angus Shalem Leemaqz Olivia Ooi Pauline Cundill Nicholas Silberstein Peter Locke Jeffrey D Zajac Ada S Cheung |
| author_facet | Lachlan Angus Shalem Leemaqz Olivia Ooi Pauline Cundill Nicholas Silberstein Peter Locke Jeffrey D Zajac Ada S Cheung |
| author_sort | Lachlan Angus |
| collection | DOAJ |
| description | Background: Oestradiol with or without an anti-androgen (cyproterone acetate or spironolactone) is commonly prescribed in transfeminine individuals who have not had orchidectomy; however, there is no evidence to guide optimal treatment choice.
Objective: We aimed to compare add-on cyproterone acetate versus spironolactone in lowering endogenous testosterone concentrations in transfeminine individuals.
Design: Retrospective cross-sectional study.
Methods: We analysed 114 transfeminine individuals who had been on oestradiol therapy for >6 months in two gender clinics in Melbourne, Australia. Total testosterone concentrations were compared between three groups; oestradiol alone (n = 21), oestradiol plus cyproterone acetate (n = 21) and oestradiol plus spironolactone (n = 38). Secondary outcomes included serum oestradiol concentration, oestradiol valerate dose, blood pressure, serum potassium, urea and creatinine.
Results: Median age was 27.0 years (22.5–45.1) and median duration of hormone therapy was 1.5 years (0.9–2.6), which was not different between groups. On univariate analysis, the cyproterone group had significantly lower total testosterone concentrations (0.8 nmol/L (0.6–1.20)) compared with the spironolactone group (2.0 nmol/L (0.9–9.4), P = 0.037) and oestradiol alone group (10.5 nmol/L (4.9–17.2), P < 0.001), which remained significant (P = 0.005) after adjustments for oestradiol concentration, dose and age. Serum urea was higher in the spironolactone group compared with the cyproterone group. No differences were observed in total daily oestradiol do se, blood pressure, serum oestradiol, potassium or creatinine.
Conclusions: The cyproterone group achieved serum total testosterone concentrations in the female reference range. As spironolactone may cause feminisation without inhibition of steroidogenesis, it is unclear which anti-androgen is more effective at feminisation. Further prospective studies are required. |
| first_indexed | 2024-12-12T15:00:31Z |
| format | Article |
| id | doaj.art-1bc34af7061746dda24eb2203cbf9268 |
| institution | Directory Open Access Journal |
| issn | 2049-3614 2049-3614 |
| language | English |
| last_indexed | 2024-12-12T15:00:31Z |
| publishDate | 2019-07-01 |
| publisher | Bioscientifica |
| record_format | Article |
| series | Endocrine Connections |
| spelling | doaj.art-1bc34af7061746dda24eb2203cbf92682022-12-22T00:20:48ZengBioscientificaEndocrine Connections2049-36142049-36142019-07-0187935940https://doi.org/10.1530/EC-19-0272Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapyLachlan Angus0Shalem Leemaqz1Olivia Ooi2Pauline Cundill3Nicholas Silberstein4Peter Locke5Jeffrey D Zajac6Ada S Cheung7Department of Medicine (Austin Health), The University of Melbourne, Heidelberg, Victoria, AustraliaRobinson Research Institute, Adelaide Medical School, The University of Adelaide, Adelaide, South AustraliaDepartment of Medicine (Austin Health), The University of Melbourne, Heidelberg, Victoria, AustraliaEquinox Gender Diverse Clinic, Thorne Harbour Health, Fitzroy, Victoria, AustraliaEquinox Gender Diverse Clinic, Thorne Harbour Health, Fitzroy, Victoria, AustraliaEquinox Gender Diverse Clinic, Thorne Harbour Health, Fitzroy, Victoria, AustraliaDepartment of Medicine (Austin Health), The University of Melbourne, Heidelberg, Victoria, AustraliaDepartment of Medicine (Austin Health), The University of Melbourne, Heidelberg, Victoria, AustraliaBackground: Oestradiol with or without an anti-androgen (cyproterone acetate or spironolactone) is commonly prescribed in transfeminine individuals who have not had orchidectomy; however, there is no evidence to guide optimal treatment choice. Objective: We aimed to compare add-on cyproterone acetate versus spironolactone in lowering endogenous testosterone concentrations in transfeminine individuals. Design: Retrospective cross-sectional study. Methods: We analysed 114 transfeminine individuals who had been on oestradiol therapy for >6 months in two gender clinics in Melbourne, Australia. Total testosterone concentrations were compared between three groups; oestradiol alone (n = 21), oestradiol plus cyproterone acetate (n = 21) and oestradiol plus spironolactone (n = 38). Secondary outcomes included serum oestradiol concentration, oestradiol valerate dose, blood pressure, serum potassium, urea and creatinine. Results: Median age was 27.0 years (22.5–45.1) and median duration of hormone therapy was 1.5 years (0.9–2.6), which was not different between groups. On univariate analysis, the cyproterone group had significantly lower total testosterone concentrations (0.8 nmol/L (0.6–1.20)) compared with the spironolactone group (2.0 nmol/L (0.9–9.4), P = 0.037) and oestradiol alone group (10.5 nmol/L (4.9–17.2), P < 0.001), which remained significant (P = 0.005) after adjustments for oestradiol concentration, dose and age. Serum urea was higher in the spironolactone group compared with the cyproterone group. No differences were observed in total daily oestradiol do se, blood pressure, serum oestradiol, potassium or creatinine. Conclusions: The cyproterone group achieved serum total testosterone concentrations in the female reference range. As spironolactone may cause feminisation without inhibition of steroidogenesis, it is unclear which anti-androgen is more effective at feminisation. Further prospective studies are required.https://ec.bioscientifica.com/view/journals/ec/8/7/EC-19-0272.xmltransgender personstranssexualismgender identitygender dysphoriaandrogens |
| spellingShingle | Lachlan Angus Shalem Leemaqz Olivia Ooi Pauline Cundill Nicholas Silberstein Peter Locke Jeffrey D Zajac Ada S Cheung Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy Endocrine Connections transgender persons transsexualism gender identity gender dysphoria androgens |
| title | Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy |
| title_full | Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy |
| title_fullStr | Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy |
| title_full_unstemmed | Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy |
| title_short | Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy |
| title_sort | cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy |
| topic | transgender persons transsexualism gender identity gender dysphoria androgens |
| url | https://ec.bioscientifica.com/view/journals/ec/8/7/EC-19-0272.xml |
| work_keys_str_mv | AT lachlanangus cyproteroneacetateorspironolactoneinloweringtestosteroneconcentrationsfortransgenderindividualsreceivingoestradioltherapy AT shalemleemaqz cyproteroneacetateorspironolactoneinloweringtestosteroneconcentrationsfortransgenderindividualsreceivingoestradioltherapy AT oliviaooi cyproteroneacetateorspironolactoneinloweringtestosteroneconcentrationsfortransgenderindividualsreceivingoestradioltherapy AT paulinecundill cyproteroneacetateorspironolactoneinloweringtestosteroneconcentrationsfortransgenderindividualsreceivingoestradioltherapy AT nicholassilberstein cyproteroneacetateorspironolactoneinloweringtestosteroneconcentrationsfortransgenderindividualsreceivingoestradioltherapy AT peterlocke cyproteroneacetateorspironolactoneinloweringtestosteroneconcentrationsfortransgenderindividualsreceivingoestradioltherapy AT jeffreydzajac cyproteroneacetateorspironolactoneinloweringtestosteroneconcentrationsfortransgenderindividualsreceivingoestradioltherapy AT adascheung cyproteroneacetateorspironolactoneinloweringtestosteroneconcentrationsfortransgenderindividualsreceivingoestradioltherapy |